Table 1 Baseline characteristics of the study population
Variables | CAVB (-) (n = 835) | CAVB (+) (n = 48) | p-value | |
|---|---|---|---|---|
Age | 59.1 ± 12.7 | 70.7 ± 10.7 | < 0.001 | |
Male, n (%) | 687 (82) | 30 (63) | 0.001 | |
Diabetes mellitus, n (%) | 209 (25) | 16 (33) | 0.199 | |
Hypertension, n (%) | 335 (40) | 22 (46) | 0.433 | |
Previous CAD, n (%) | 172 (21) | 9 (19) | 0.758 | |
Previous CHF, n (%) | 37 (4) | 3 (6) | 0.556 | |
Chronic kidney disease, n (%) | 50 (6) | 9 (19) | < 0.001 | |
Previous stroke, n (%) | 46 (6) | 3 (6) | 0.827 | |
Hyperlipidemia, n (%) | 112 (13) | 6 (13) | 0.857 | |
Multivessel disease, n (%) | 419 (51) | 31 (65) | 0.219 | |
Smoking, n (%) | 431 (52) | 18 (38) | 0.057 | |
Inotrope usage, n (%) | 55 (7) | 17 (35) | < 0.001 | |
Killip class > 2, n (%) | 102 (12) | 23 (48) | < 0.001 | |
IABP usage, n (%) | 55 (7) | 17 (3575) | < 0.001 | |
Thrombus aspiration device, n (%) | 140 (17) | 20 (42) | < 0.001 | |
GpIIB3A inhibitors, n (%) | 293 (35) | 22 (46) | 0.131 | |
Final TIMI-3 flow n (%) | 745 (89) | 36 (75) | 0.003 | |
Infarct related artery, n (%) | < 0.001 | |||
LMCA, n (%) | 9 (1) | 2 (4) | ||
LAD, n (%) | 374 (45) | 9 (19) | ||
CX, n (%) | 92 (11) | 3 (6) | ||
RCA, n (%) | 275 (33) | 32 (67) | ||
Others n (%) | 59 (7) | 1 (2) | ||
Medical treatment at discharge, n (%) | 90 (51) | 19 (66) | 0.159 | |
Aspirin n (%) | 738 (97) | 26 (90) | 0.016 | |
Clopidogrel, n (%) | 523 (69) | 22 (73) | 0.600 | |
Prasuqrel, n (%) | 64 (8) | 0 (0) | 0.097 | |
Tigacrelor, n (%) | 151 (20) | 5 (17) | 0.661 | |
Beta blockers, n (%) | 670 (88) | 18 (60) | < 0.001 | |
ACE/ARB, n (%) | 627 (83) | 18 (64) | 0.048 | |
Statin n (%) | 708 (93) | 26 (90) | 0.726 | |
Outcomes | ||||
In-hospital mortality, n (%) | 75 (9) | 22 (46) | < 0.001 | |
Long-term mortality, n (%) | 164 (20) | 13 (27) | 0.210 | |